IMRX
USDImmuneering Corporation Class A Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$1.470
Máximo
$1.490
Mínimo
$1.430
Volumen
0.01M
Fundamentos de la Empresa
Capitalización de Mercado
52.5M
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.20M
Bolsa
NGM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
Acciones Relacionadas
FAX
abrdn Asia-Pacific Income Fund Inc.
CTVA
Corteva Inc.
BZH
Beazer Homes USA Inc.
GBAB
Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust Common Shares of Beneficial Interest
DUOL
Duolingo Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.